Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
We read with interest the recent report, “Response of Dystrophic Calcification to Intravenous Immunoglobulin,” by Schanz et al1 detailing the response to intravenous immunoglobulin (IVIg) of 1 patient with CREST syndrome–associated dystrophic calcification (CREST syndrome includes calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia). Because the more traditional medical therapies, including warfarin, diltiazem hydrochloride, probenecid, colchicine, and bisphosphonates, are seldom reliable, newer safe and effective therapies are sought.2 Unfortunately, while the success reported by Schanz et al is encouraging, we have experienced less success with IVIg therapy for dermatomyositis-associated dystrophic calcification.
Kalajian AH, Perryman JH, Callen JP. Intravenous Immunoglobulin Therapy for Dystrophic Calcinosis Cutis: Unreliable in Our Hands. Arch Dermatol. 2009;145(3):334. doi:10.1001/archdermatol.2008.620
Customize your JAMA Network experience by selecting one or more topics from the list below.